
Optimal Therapies in Advanced and Recurrent Cervical Cancer



Robert L. Coleman, M.D. Department of Gynecologic Oncology University of Texas, MD Anderson Cancer Center

Disclosures

- Research Grant Funding:
 - OCRP, CPRIT, NCI (P50, N01), V-Foundation
 - Amgen, AstraZeneca, Clovis, Esperance, Genentech/Roche, Janssen, Merck, Novartis, Oncomed
- Scientific Steering/Advisory Committee (uncompensated):
 - Amgen, AstraZeneca, Endocyte, Esperance, GSK, Genentech/Roche, Janssen, Morphotek/Easai, Merck, Medimmune, Venti,

- In September 2014 a 37-year-old woman, presented to the emergency room with odorous vaginal discharge and back pain
 - No Pap or HPV test in last 5 years
- Pre-existing conditions:
 - No other significant medical history
- Evaluation:
 - Physical examination: Necrotic fixed pelvic tumor and palpable 3-cm left supraclavicular lymph node
 - Cervix biopsy: grade 3 carcinoma
 - Fine needle aspiration of supraclavicular lymph node: grade 3 carcinoma
 - PS=0

Pretreatment PET/CT Scan

Outcome

Treatment

Patient History

Diagnosis



Clinical diagnosis: FIGO stage IVB

CT=computed tomography; FIGO=International Federation of Gynecology and Obstetrics; PET=positron emission tomography.

Discussion Questions

- How does one choose the chemotherapy backbone in treating metastatic cervical cancer?
- Is this the sort of patient that would benefit from bevacizumab?

Phase III Development: Advanced Stage/Recurrent Cervix Cancer

Single Agent Platinum

- GOG 43 (1987)
 - High dose (100 mg/m²), better response, no difference in OS
- GOG 64 (1989)
 - Infusion schedule, no difference
- GOG 77 (1989)
 - Platinum analogs "probably" no better

Combination Platinum Regimens

- GOG 110 (1997)
 - If ex improved response, no diff in OS
- GOG149 (2002)
 - Bleo adds nothing to cis/ifex
- GOG 169 (2004)*
 - Paclitaxel improves RR, PFS but not OS
- GOG 179 (2005)*
 - Topo/cis improves RR, PFS and OS
- GOG 204 (2009)
 - No "winner"; pac/cis better therapeutic index

*Trials spanned incorporation of platinum-based chemo-XRT



Cisplatin/Paclitaxel vs. Carboplatin/Paclitaxel: JCOG 0505 trial



127 assigned to cisplatin-paclitaxel

Paclitaxel **135** mg/m² **24h** d1 Cisplatin 50 mg/m² 2h **d2** 126 assigned to carboplatin-paclitaxel

Paclitaxel **175** mg/m² **3h** d1 Carboplatin AUC 5 1h **d1**

Maximum 6 cycles of treatment


until disease progression or unacceptable toxicity

JCOG 0505 trial, Kitawaga R, J Clin Oncol 2015

Non-inferiority design (HR:1.29)



No difference in PFS and OS




JCOG 0505 trial, Kitawaga R et al JCO 2015

Toxicity: Balance Slightly in Favor of Carboplatin

	Grade	Cisplatin + paclitaxel	Carboplatin + paclitaxel	р
Neutropenia	<u>></u> 3	85	76	<0.0001
Febrile neutropenia		16	7	0.03
Infection		5	5	
Platelets		3	25	
Anemia		31	44	
Fatigue	<u>></u> 2	17	16	
Vomiting		30	20	
Creatinine		7	5	
Neurological		14	22	
% of non-hospitalization period		46.4	61.9	< 0.0001




Effects on OS of Prior Platinum



JCOG 0505 trial, Kitawaga R et al, JCO 2015

Tumor Hypoxia and Viral Oncogenes Drive Angiogenesis




Bevacizumab activity in cervical cancer was demonstrated in a phase II single-agent study (GOG 227C)

GOG, Gynecologic Oncology Group; HDAC, histone deacetylase; HIF1α, hypoxia-inducible factor 1-alpha; HPV, human papilloma virus; pRb, retinoblastoma protein; TSP1, thrombospondin 1; VEGF, vascular endothelial growth factor.

Tewari KS, et al. Gynecol Oncol 2000;77:137-48. Monk BJ, et al. J Clin Oncol 2009;27:1069-74.

MicrobiologyBytes. Available at: http://www.microbiologybytes.com/virology/Papillomaviruses.html. Accessed September 9, 2014.

GOG 240: Schema



chemo, chemotherapy; CR, complete response; GOG, Gynecologic Oncology Group; PD, progressive disease; PS, performance status; q21d, every 21 days; Rx, treatment KS Tewari (study chair). www.ClinicalTrials.gov Identifier: NCT00803062.

Closed to accrual: 1/3/12

Tewari NEJM 2014

GOG 240 Objectives


- Primary end points to determine
 - Primary endpoint was overall survival (OS)
 - The efficacy of the addition of bevacizumab to chemotherapy
 - The efficacy of chemotherapy doublets; platinum vs non-platinum (topotecan + paclitaxel)
 - The tolerability of the 4 regimens
- Secondary end points to determine
 - Progression-Free Survival: PFS
 - Overall response rate (ORR) by Response Evaluation Criteria In Solid Tumors v1.0
- Exploratory end points
 - Impact on health-related quality of life (HRQoL):
 - Functional Assessment of Cancer Therapy Cervix Ca Trial Outcome Index
 - Data not included in current presentation
 - Additional HRQoL: Gynecologic Oncology Group neurotoxicity, Brief Pain Inventory
 - Prospective validation of pooled clinical prognostic factors from prior phase III trials
 - Prevalence and impact of nicotine dependence on OS and PFS
 - Circulating tumor cells and vascular endothelial growth factor (VEGF) isoform expression

GOG 240 – Demographics & Baseline Characteristics

Characteristic	Chemo Alone (n=225), %	Chemo + Bev (n=227), %
Median age, years (range)	46 (20–83)	48 (22–85)
Histology, %		
Squamous	68	70
Adenocarcinoma, unspec.	20	19
Race, %		
White	80	75
African American	11	16
Asian	3	5
Pacific Islander	0	0
Stage of disease, %		
Recurrent	73	70
Persistent	10	12
Advanced	16	17
Performance status, %		
0	58	58
1	42	42
Prior platinum, %	74	75
Pelvic disease, %	53	54


Bev, bevacizumab; chemo, chemotherapy; GOG, Gynecologic Oncology Group; unspec., unspecified.


Interim Analysis: Topo/pac vs cis/pac



GOG-0240: Final OS/PFS

В






Tewari NEJM 2014

GOG-0240: Individual Arms ± Bev


D

TP



С

Median Overall **Events** Survival no. (%) mo 71 (64) 12.7 — TP (N=111) 16.2 65 (58) — TP+Bev (N=112) Hazard ratio, 0.74 (95% CI, 0.53-1.05); one-sided P=0.09



Tewari NEJM 2014

GOG-0240: Subgroup Analysis

Subgroup		No. of Patients			Hazar	d Ratio		
Age	≤40 yr	112				-		
0	40 to ≤48 yr	111						
	48 to ≤56 yr	108						
	>56 yr	121						
Performance status	0	263						
	1	189						
Previous platinum radiation therapy	Νο	115						
	Yes	337						
Disease status	Advanced	76						
	Recurrent or persistent	376						
Topotecan treatment	No	229		-				
	Yes	223						
Race	Not black	392						
	Black	60	-	-				
Histologic type	Adenocarcinoma	86						-
	Adenosquamous	44	-				-	
	Other	12						
	Squamous	310			-			
Pelvic disease	No	210						
	Yes	242						
Overall		452						
		(0.0	0.5	1.0	1.5	2.0	2.5
			Experimental Better		Conti	rol Better		

GOG-240: Moore Risk Stratification

- Planned subgroup analysis
- Moore risk criteria established on 429 patients treated on GOG-110, GOG-169, GOG-179 and validated in GOG-149 (all phase III trials)

Factor	Points		
	0	1	
Performance Status	0	>0	
Pelvic Disease	Absent	Present	
African American	No	Yes	
Disease Free Interval	≥ 12 mos	<12 mos	
Prior Platinum	No	Yes	

Risk:

- Low: 0-1
- Mid: 2-3
- High: 4-5

Tewari et al.Clin Cancer Res; 21(24) December 15, 2015


GOG 240: Validation of The Moore Criteria Entire Study Population: Arms 1-4

Total

84

303


65



	Median OS (months)	Median PFS (months)	RR (%)
Low-risk	21.8	9.2	57.1
Mid-risk	14.7	6.9	43.2
High-risk	8.2	4.7	18.5
P (likelihood ratio)	<.0001	.0050	<.0001


Tewari KS, et al. Presented at: Society of Gynecologic Oncology 45th Annual Meeting on Women's Cancer; March 22-25, 2014; Tampa, Flordia. Abstract 44-45.

Overall Survival by Regimen: Low Risk




Tewari et al.Clin Cancer Res; 21(24) December 15, 2015

Overall Survival by Regimen: Mid Risk




Tewari et al.Clin Cancer Res; 21(24) December 15, 2015

Overall Survival by Regimen: High Risk



Objective Response



GOG/NRG Oncology CTCAE v 3,4 Updated Toxicity Profile

Adverse Event, n (%)	Chemo Alone (n=220)	Chemo + Bev (n=220)
Treatment cycles, median (range)	6 (1-50)	7 (1-40)
Grade 5 AE(s)	3 (1.3)	7 (3.2)
GI events, non-fistula (grade ≥2)	97 (44)	115 (53)
GI fistula (grade ≥2)	1(0.5)	11 (5)
GI perforation (grade ≥2)	0 (0)	5 (2.3)
GU fistula (grade ≥2)	1 (0.5)	8 (3.6)
Hypertension (grade ≥2)	4 (1.8)	55 (25)
Proteinuria (grade ≥3)	0 (0)	5 (2.3)
Pain (grade ≥2)	63 (29)	72 (33)
Neutropenia (grade ≥4)	58 (26)	80 (36)
Febrile neutropenia (grade <u>></u> 3)	12 (5.5)	12 (5.5)
Thromboembolism (grade ≥3)	4 (1.8)	18 (8.2)
Bleeding CNS (any grade)	0 (0)	0 (0)
GI (grade ≥3)	1 (0.5)	4 (1.8)
GU (grade ≥3)	1 (0.5)	6 (2.7)

All patients developing fistula had previous pelvic RT (IGCS 2014)

bev, bevacizuamb; chemo, chemotherapy; CNS, central nervous system; GI, gastrointestinal; GU, genitourinary.

Tewari NEJM 2014

- The patient started on IV cisplatin 50 mg/m², paclitaxel 175 mg/m² over 3 hours and bevacizumab 15 mg/kg q3w × 6 cycles
- Patient tolerated treatment well C5 dose delay for 1 week due to hypertension management
- PET/CT repeated after cycle 6

Avastin[®] (bevacizumab) [prescribing information]. South San Francisco, CA: Genentech, Inc.; 2014.

- Patient has responses in lymph nodes and primary tumor after cycle 4
- Patient continued on cisplatin, paclitaxel and bevacizumab
- Repeat PET/CT = NED, treatment discontinued
- On active surveillance (3 month FUV)



Pretreatment PET/CT Scan

Sei 9 9 DFOV 112.2 cm 8.00 8.00 0.00 0.00 0.00 50 x PET 903/42 3.6/ 903/42 3.3mm /3.3sp 03:43:33 PM m=0.00 M=8.00 g/m1 I 1006 V=1.54

PET/CT After Cycle 4

Discussion Questions

- What is the role of maintenance bevacizumab?
 - In GOG-0240, 21/28 CR's discontinued therapy
- Does this patient need radiation now that there has been a CR?
 - Should chemotherapy (+/- bevacizumab) be added to radiation?
 - Should this include brachytherapy or just external beam?
- What is her risk of a fistula?
 - If a fistula occurs on therapy, how is this managed?
- What are the options for recurrence should it occur?

New Directions

- Immunotherapy and immunomodulators
 - PD1/PDL-1, CTLA-4, OX-40, 4-1BB, KIR
 - HPV therapeutic vaccines
 - ADXS-HPV
- PARP
- PI3K & MAPK pathway inhibitors
- Angiogenesis
 - Escape (infiltrating macrophages/monocytes, MDSC's, TIL targeting)
 - Нурохіа
 - New targets (Ang1/2, FGFR, TKI's)

Summary

- Platinum-paclitaxel combination is the standard chemotherapy in patients with adequate PS and renal function
- Carboplatin is a reasonable substitute for cisplatin
- Bevacizumab added to standard chemotherapy prolongs overall survival, without a significant impact on QoL
- More agents = more toxicity (legitimate concerns for fistula in radiated patients)
- Next step is to optimize the use of bevacizumab and to integrate new targeted therapies



SUCCESS

Because you too can own this face of pure accomplishment

DIV.DESPAIR.COM

rcoleman@mdanderson.org